Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
Dogwood Therapeutics announced the commencement of a 12-week open-label extension study for its lead asset Halneuron in chemotherapy-induced neuropathic pain (CINP). The decision follows a positive interim assessment of the ongoing Phase 2b double-blinded study, which showed a treatment effect versus placebo in 97 patients and a dropout rate under 5%.
Key figures
- Drug Name
- Halneuron
- Phase Of Trial
- Phase 2b
- Dropout rate
- <5%
- Target sample size
- 210-240
- Interim patient count
- 97
- Mean symptom duration
- 5 years
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.